APA (7th ed.) Citation

L, B., E, A., S, F., C, B., L, C., S, D., . . . F, M. (2026). CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas. Leukemia, 40(8), 1735. https://doi.org/10.1038/s41375-026-03018-w

Chicago Style (17th ed.) Citation

L, Babin, et al. "CircZBTB46, a Promising Therapeutic Target in Crizotinib Resistant ALK-positive T Lymphomas." Leukemia 40, no. 8 (2026): 1735. https://doi.org/10.1038/s41375-026-03018-w.

MLA (9th ed.) Citation

L, Babin, et al. "CircZBTB46, a Promising Therapeutic Target in Crizotinib Resistant ALK-positive T Lymphomas." Leukemia, vol. 40, no. 8, 2026, p. 1735, https://doi.org/10.1038/s41375-026-03018-w.